{"id":7908,"date":"2025-06-26T17:00:36","date_gmt":"2025-06-27T00:00:36","guid":{"rendered":"https:\/\/rakuten-med.com\/us\/?post_type=press_releases&#038;p=7908"},"modified":"2025-06-26T16:22:35","modified_gmt":"2025-06-26T23:22:35","slug":"rakuten-medical-and-orient-europharma-sign-exclusive-licensing-agreement-to-co-develop-and-commercialize-alluminox-platform-based-photoimmunotherapy-in-taiwan-and-southeast-asia","status":"publish","type":"press_releases","link":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2025\/06\/26\/7908\/","title":{"rendered":"Rakuten Medical and Orient EuroPharma Sign Exclusive Licensing Agreement for Alluminox\u2122 Platform-based Photoimmunotherapy in Taiwan, Malaysia, Singapore, and the Philippines"},"content":{"rendered":"<div id=\"pl-7908\"  class=\"panel-layout\" ><div id=\"pg-7908-0\"  class=\"panel-grid panel-no-style\"  style=\"margin-bottom: 0px\" ><div id=\"pgc-7908-0-0\"  class=\"panel-grid-cell\" ><div id=\"panel-7908-0-0-0\" class=\"so-panel widget widget_sow-editor panel-first-child panel-last-child\" data-index=\"0\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-editor so-widget-sow-editor-base\"\n\t\t\t\n\t\t>\n<div class=\"siteorigin-widget-tinymce textwidget\">\n\t<ul>\n<li aria-level=\"1\"><em><strong>OEP\/Cyntec to bring Rakuten Medical\u2019s innovative cancer therapies to new markets<\/strong><\/em><\/li>\n<li aria-level=\"1\"><em><strong>Rakuten Medical to receive upfront payment and potential milestones and royalties based on future sales<\/strong><\/em><\/li>\n<\/ul>\n<\/div>\n<\/div><\/div><\/div><\/div><div id=\"pg-7908-1\"  class=\"panel-grid panel-no-style\"  style=\"margin-bottom: 0px\" ><div id=\"pgc-7908-1-0\"  class=\"panel-grid-cell\" ><div id=\"panel-7908-1-0-0\" class=\"so-panel widget widget_sow-editor panel-first-child panel-last-child\" data-index=\"1\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-editor so-widget-sow-editor-base\"\n\t\t\t\n\t\t>\n<div class=\"siteorigin-widget-tinymce textwidget\">\n\t<p><b>San Diego, CA, and Taipei, Taiwan \u2013 <\/b><span style=\"font-weight: 400\">Rakuten Medical, Inc. (\u201cRMI\u201d) and Orient EuroPharma Co., Ltd. (\u201cOEP\u201d) today announced the signing of an exclusive licensing agreement (\u201cAgreement\u201d) between RMI and Cyntec Co., Ltd. (\u201cCyntec\u201d), an affiliate of OEP, to co-develop and commercialize photoimmunotherapy products based on RMI\u2019s proprietary Alluminox\u2122 platform in Taiwan, Malaysia, Singapore, and the Philippines (collectively, the \u201cTerritory\u201d).<\/span><\/p>\n<p><span style=\"font-weight: 400\">The Alluminox\u2122 platform-based photoimmunotherapy is RMI\u2019s innovative cancer treatment modality, which combines a drug with devices for localized light illumination. This novel therapeutic approach has been observed in pre-clinical studies to induce rapid and selective depletion of cancer and\/or immunosuppressive cells with minimal impact on surrounding healthy tissue. This precision targeting may help preserve critical functions and quality of life for patients. Moreover, pre-clinical observations have shown that photoimmunotherapy may also stimulate both innate and adaptive anti-tumor immune responses, suggesting the possibility of sustained anti-tumor effects. These features may position Alluminox\u2122 platform-based photoimmunotherapy as a novel form of precision, immune-activating surgery.<\/span><\/p>\n<p><span style=\"font-weight: 400\">Under the Agreement, Cyntec will lead the co-development, regulatory filings, and commercialization of Alluminox\u2122 platform-based products \u2013 both drugs and devices \u2013 in the Territory. RMI will support Cyntec throughout these activities by providing scientific, clinical and commercial expertise.<\/span><\/p>\n<p><span style=\"font-weight: 400\">RMI will receive an upfront payment in consideration for the Agreement from Cyntec. RMI is also eligible to receive milestones and royalties tied to future net sales of Alluminox\u2122 platform-based products in the Territory.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400\">Commenting on the signing of the Agreement, Mickey Mikitani, CEO of Rakuten Medical stated, \u201cThis agreement significantly expands our opportunity to contribute to healthcare across a broader region of Asia through our innovative Alluminox\u2122 platform. We have a strong team across the globe\u2014including Taiwan, the United States and Japan\u2014where everyone is working closely to strengthen the scientific foundation of the platform while advancing our therapy through real-world clinical experience both in global clinical trials and commercial use in Japan. We are excited to collaborate with OEP and Cyntec to accelerate the availability of our treatment to patients in Taiwan, Malaysia, Singapore, and the Philippines, and to take another key step toward fulfilling our mission.\u201d<\/span><\/p>\n<p><span style=\"font-weight: 400\">\u201cThis partnership is not only a strategic business opportunity but also a reflection of OEP\u2019s long-term commitment to patient care,\u201d said Peter Tsai, Chairman of OEP. \u201cWe are committed to driving the localization and adoption of Alluminox\u2122 platform-based photoimmunotherapy, expediting its path to market, and expanding its clinical and commercial value across the Territory.\u201d<\/span><\/p>\n<\/div>\n<\/div><\/div><\/div><\/div><div id=\"pg-7908-2\"  class=\"panel-grid panel-no-style\"  style=\"margin-bottom: 0px\" ><div id=\"pgc-7908-2-0\"  class=\"panel-grid-cell\" ><div id=\"panel-7908-2-0-0\" class=\"so-panel widget widget_sow-image panel-first-child\" data-index=\"2\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-image so-widget-sow-image-default-8b5b6f678277-7908\"\n\t\t\t\n\t\t>\n<div class=\"sow-image-container\">\n\t\t<img \n\tsrc=\"https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2025\/06\/P-1.-Press-release-photo.jpg\" width=\"1566\" height=\"1044\" srcset=\"https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2025\/06\/P-1.-Press-release-photo.jpg 1566w, https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2025\/06\/P-1.-Press-release-photo-300x200.jpg 300w, https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2025\/06\/P-1.-Press-release-photo-1024x683.jpg 1024w, https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2025\/06\/P-1.-Press-release-photo-768x512.jpg 768w, https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2025\/06\/P-1.-Press-release-photo-1536x1024.jpg 1536w, https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2025\/06\/P-1.-Press-release-photo-272x182.jpg 272w, https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2025\/06\/P-1.-Press-release-photo-360x240.jpg 360w\" sizes=\"(max-width: 1566px) 100vw, 1566px\" title=\"P-1. Press release photo\" alt=\"\" \t\tclass=\"so-widget-image\"\/>\n\t<\/div>\n\n<\/div><\/div><div id=\"panel-7908-2-0-1\" class=\"so-panel widget widget_sow-editor panel-last-child\" data-index=\"3\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-editor so-widget-sow-editor-base\"\n\t\t\t\n\t\t>\n<div class=\"siteorigin-widget-tinymce textwidget\">\n\t<p><span style=\"font-weight: 400;\">Partnership Ceremony (From left)<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Minami Maeda, President of Rakuten Medical, Inc.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Dr. Yi-Shing Leu, Chairman of the Taiwan Head and Neck Cancer Society<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Louise Chang, Managing Director, Rakuten Medical Taiwan, Inc.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Dr. Kuan-Chou Lin, Former President of the Chinese Society of Oral and Maxillofacial Surgery<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Calvin Tsai, Chief Executive Officer of OEP<\/span><\/li>\n<\/ul>\n<\/div>\n<\/div><\/div><\/div><\/div><div id=\"pg-7908-3\"  class=\"panel-grid panel-no-style\"  style=\"margin-bottom: 0px\" ><div id=\"pgc-7908-3-0\"  class=\"panel-grid-cell\" ><div id=\"panel-7908-3-0-0\" class=\"so-panel widget widget_sow-editor panel-first-child panel-last-child\" data-index=\"4\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-editor so-widget-sow-editor-base\"\n\t\t\t\n\t\t>\n<div class=\"siteorigin-widget-tinymce textwidget\">\n\t<p><span style=\"font-weight: 400\">Rakuten Medical\u2019s lead drug ASP-1929 (marketed in Japan as Akalux\u00ae) and device system (marketed in Japan as BioBlade\u00ae) received the world\u2019s first regulatory approval in Japan in 2020 for unresectable locally advanced or recurrent head and neck cancer, under the Sakigake Designation System and the Conditional Early Approval System. Since its commercial launch in January 2021, the therapy\u2019s presence has grown steadily. Today, ASP-1929 photoimmunotherapy is available in all 47 Japanese prefectures, with nearly 1,000 treatments delivered across more than 180 medical facilities by over 450 physicians.<\/span><\/p>\n<p><i><span style=\"font-weight: 400\">Disclaimer: Rakuten Medical\u2019s Alluminox\u2122 platform-based photoimmunotherapy is investigational outside Japan.<\/span><\/i><\/p>\n<p><span style=\"font-weight: 400\">Real-world data from Japan has shown a manageable safety profile and encouraging efficacy, including an Overall Response Rate (ORR) exceeding 68% and a Complete Response (CR) rate of over 30 % in head and neck cancer<\/span><sup>1<\/sup><span style=\"font-weight: 400\"> as well as a CR rate of over 73% in nasopharyngeal cancer<\/span><sup>2<\/sup><span style=\"font-weight: 400\">.<\/span><\/p>\n<p><span style=\"font-weight: 400\">ASP-1929 photoimmunotherapy in combination with pembrolizumab is currently being investigated in a global Phase 3 trial in Taiwan and the United States as a first-line treatment for recurrent head and neck cancer. (Protocol number: ASP-1929-381 \/ Acronym: ECLIPSE \/ ClinicalTrials.gov Identifier: <\/span><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06699212\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400\">NCT06699212<\/span><\/a><span style=\"font-weight: 400\">). A prior Phase 1b\/2 study showed <\/span><a href=\"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2024\/05\/24\/7847\/\"><span style=\"font-weight: 400\">promising interim evaluation results<\/span><\/a><span style=\"font-weight: 400\">, including a 24-month survival rate of 52.4% and a median overall survival (OS) not yet reached<\/span><sup>3<\/sup><span style=\"font-weight: 400\">. <\/span><\/p>\n<\/div>\n<\/div><\/div><\/div><\/div><div id=\"pg-7908-4\"  class=\"panel-grid panel-no-style\"  style=\"margin-bottom: 0px\" ><div id=\"pgc-7908-4-0\"  class=\"panel-grid-cell\" ><div id=\"panel-7908-4-0-0\" class=\"so-panel widget widget_sow-editor panel-first-child panel-last-child\" data-index=\"5\" ><div class=\"panel-widget-style panel-widget-style-for-7908-4-0-0\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-editor so-widget-sow-editor-base\"\n\t\t\t\n\t\t>\n<div class=\"siteorigin-widget-tinymce textwidget\">\n\t<ol>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Akalux IV Infusion 250 mg Post-Marketing Surveillance (all-case survey)\u00a0 Interim Analysis (Data Cutoff Date: 2024\/9\/24)<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Takeshi Shinozaki, et al. Photoimmunotherapy in nasopharyngeal carcinoma recurrence. Poster presented at: 2024 ASCO Annual Meeting.<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">David M. Cognetti, et al. Recent safety and efficacy findings from a phase 1b\/2 open-label combination study of ASP-1929 photoimmunotherapy with anti-PD-1 therapy in EGFR-expressing advanced head and neck squamous cell carcinoma (HNSCC). Poster presented at: 2024 ASCO Annual Meeting.<\/span><\/li>\n<\/ol>\n<p>&nbsp;<\/p>\n<p><b>About Rakuten Medical, Inc.<br \/>\n<\/b><span style=\"font-weight: 400\">Rakuten Medical, Inc. is a global biotechnology company developing and commercializing Alluminox\u2122 platform-based photoimmunotherapy, which, in pre-clinical studies, has been shown to induce rapid and selective cell killing. Rakuten Medical\u2019s photoimmunotherapy is currently investigational outside Japan. Rakuten Medical is committed to its mission to conquer cancer by developing its pioneering treatments as quickly as possible to as many patients as possible all over the world. The company has offices in 5 countries\/regions, including the United States, where it is headquartered, Japan, Taiwan, Switzerland and India. For more information, visit <\/span><a href=\"http:\/\/www.rakuten-med.com\"><span style=\"font-weight: 400\">www.rakuten-med.com<\/span><\/a><span style=\"font-weight: 400\">.<\/span><\/p>\n<p><b>About Alluminox\u2122 platform<br \/>\n<\/b><span style=\"font-weight: 400\">The Alluminox\u2122 platform is Rakuten Medical\u2019s investigational technology platform that combines pharmaceuticals, medical devices, medical technology, and other peripheral technologies. Rakuten Medical is developing Alluminox platform-based photoimmunotherapy, which involves two key steps: 1) drug administration and 2) targeted illumination using medical devices. The drug component consists of a cell-targeting moiety conjugated to a light-activatable dye, such as IRDye\u00ae 700DX (IR700), that selectively binds to the surface of targeted cells, such as tumor cells. The device component consists of a light source that locally illuminates the targeted cells with red light (690nm) to transiently activate the drug. Rakuten Medical\u2019s pre-clinical data have shown that this activation elicits rapid and selective necrosis of targeted cells through a biophysical process that compromises the membrane integrity of the targeted cells. Therapies developed on the Alluminox platform may also result in local and systemic innate and adaptive immune activation due to immunogenic cell death of the targeted tumor cells and\/or the removal of targeted immunosuppressive cells within the tumor microenvironment. Photoimmunotherapy was originally developed by Dr. Hisataka Kobayashi and his team at the National Cancer Institute in the United States. Outside Japan, Rakuten Medical\u2019s Alluminox platform-based photoimmunotherapy is investigational.<\/span><\/p>\n<p><b>About Orient EuroPharma Co., Ltd.<\/b><b><br \/>\n<\/b><span style=\"font-weight: 400\">Orient EuroPharma Co., Ltd. (OEP), established in 1982, has grown into a leading multinational pharmaceutical company headquartered in Taiwan. Listed on the Taipei Exchange (TPEx) since 2003. (4120.TW), OEP has built a strong presence across Southeast Asia, with extensive sales network in the region. OEP\u2019s diversified portfolio spans prescription pharmaceuticals, oncology treatments, cosmeceuticals, and infant-to-adult nutrition and health products. The company also operates a dedicated subsidiary for innovative drug development and manufacturing. With integrated capabilities in pharmaceutical R&amp;D, clinical trials, manufacturing, and regional marketing, OEP continues to advance healthcare solutions throughout Taiwan and the broader Asia-Pacific region.<\/span><\/p>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div><div id=\"pg-7908-5\"  class=\"panel-grid panel-no-style\" ><div id=\"pgc-7908-5-0\"  class=\"panel-grid-cell\" ><div id=\"panel-7908-5-0-0\" class=\"so-panel widget widget_sow-button panel-first-child panel-last-child\" data-index=\"6\" ><div style=\"padding: 30px 0px 0px 0px;\" class=\"panel-widget-style panel-widget-style-for-7908-5-0-0\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-button so-widget-sow-button-flat-6fd36f18507f-7908\"\n\t\t\t\n\t\t><div class=\"ow-button-base ow-button-align-center\"\n>\n\t\t\t<a\n\t\t\t\t\thref=\"https:\/\/rakuten-med.com\/us\/contact\/\"\n\t\t\t\t\tclass=\"rakuten-btn sowb-button ow-icon-placement-left ow-button-hover\" \t>\n\t\t<span>\n\t\t\t\n\t\t\tContact Us\t\t<\/span>\n\t\t\t<\/a>\n\t<\/div>\n<\/div><\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>OEP\/Cyntec to bring Rakuten Medical\u2019s innovative cancer therapies to new markets Rakuten Medical to receive upfront payment and potential milestones [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":7912,"template":"","meta":{"_acf_changed":false,"_genesis_hide_title":false,"_genesis_hide_breadcrumbs":false,"_genesis_hide_singular_image":false,"_genesis_hide_footer_widgets":false,"_genesis_custom_body_class":"","_genesis_custom_post_class":"","_genesis_layout":""},"class_list":{"0":"post-7908","1":"press_releases","2":"type-press_releases","3":"status-publish","4":"has-post-thumbnail","6":"entry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Rakuten Medical and Orient EuroPharma Sign Exclusive Licensing Agreement for Alluminox\u2122 Platform-based Photoimmunotherapy in Taiwan, Malaysia, Singapore, and the Philippines - Rakuten Medical - To conquer cancer.<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2025\/06\/26\/7908\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rakuten Medical and Orient EuroPharma Sign Exclusive Licensing Agreement for Alluminox\u2122 Platform-based Photoimmunotherapy in Taiwan, Malaysia, Singapore, and the Philippines - Rakuten Medical - To conquer cancer.\" \/>\n<meta property=\"og:description\" content=\"OEP\/Cyntec to bring Rakuten Medical\u2019s innovative cancer therapies to new markets Rakuten Medical to receive upfront payment and potential milestones [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2025\/06\/26\/7908\/\" \/>\n<meta property=\"og:site_name\" content=\"Rakuten Medical - To conquer cancer.\" \/>\n<meta property=\"og:image\" content=\"https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2025\/06\/P-1.-Press-release-photo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1566\" \/>\n\t<meta property=\"og:image:height\" content=\"1044\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/press-releases\\\/2025\\\/06\\\/26\\\/7908\\\/\",\"url\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/press-releases\\\/2025\\\/06\\\/26\\\/7908\\\/\",\"name\":\"Rakuten Medical and Orient EuroPharma Sign Exclusive Licensing Agreement for Alluminox\u2122 Platform-based Photoimmunotherapy in Taiwan, Malaysia, Singapore, and the Philippines - Rakuten Medical - To conquer cancer.\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/press-releases\\\/2025\\\/06\\\/26\\\/7908\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/press-releases\\\/2025\\\/06\\\/26\\\/7908\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/wp-content\\\/uploads\\\/sites\\\/6\\\/2025\\\/06\\\/P-1.-Press-release-photo.jpg\",\"datePublished\":\"2025-06-27T00:00:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/press-releases\\\/2025\\\/06\\\/26\\\/7908\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/press-releases\\\/2025\\\/06\\\/26\\\/7908\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/press-releases\\\/2025\\\/06\\\/26\\\/7908\\\/#primaryimage\",\"url\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/wp-content\\\/uploads\\\/sites\\\/6\\\/2025\\\/06\\\/P-1.-Press-release-photo.jpg\",\"contentUrl\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/wp-content\\\/uploads\\\/sites\\\/6\\\/2025\\\/06\\\/P-1.-Press-release-photo.jpg\",\"width\":1566,\"height\":1044},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/press-releases\\\/2025\\\/06\\\/26\\\/7908\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rakuten Medical and Orient EuroPharma Sign Exclusive Licensing Agreement for Alluminox\u2122 Platform-based Photoimmunotherapy in Taiwan, Malaysia, Singapore, and the Philippines\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/\",\"name\":\"Rakuten Medical - To conquer cancer.\",\"description\":\"Rakuten Medical, Inc. is a global biotechnology company developing precision, cell-targeting investigational therapies on its Alluminox\u2122TM technology platform. We are committed to our mission to conquer cancer and aim to achieve a society where cancer patients can lead fulfilling lives.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rakuten Medical and Orient EuroPharma Sign Exclusive Licensing Agreement for Alluminox\u2122 Platform-based Photoimmunotherapy in Taiwan, Malaysia, Singapore, and the Philippines - Rakuten Medical - To conquer cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2025\/06\/26\/7908\/","og_locale":"en_US","og_type":"article","og_title":"Rakuten Medical and Orient EuroPharma Sign Exclusive Licensing Agreement for Alluminox\u2122 Platform-based Photoimmunotherapy in Taiwan, Malaysia, Singapore, and the Philippines - Rakuten Medical - To conquer cancer.","og_description":"OEP\/Cyntec to bring Rakuten Medical\u2019s innovative cancer therapies to new markets Rakuten Medical to receive upfront payment and potential milestones [&hellip;]","og_url":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2025\/06\/26\/7908\/","og_site_name":"Rakuten Medical - To conquer cancer.","og_image":[{"width":1566,"height":1044,"url":"https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2025\/06\/P-1.-Press-release-photo.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2025\/06\/26\/7908\/","url":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2025\/06\/26\/7908\/","name":"Rakuten Medical and Orient EuroPharma Sign Exclusive Licensing Agreement for Alluminox\u2122 Platform-based Photoimmunotherapy in Taiwan, Malaysia, Singapore, and the Philippines - Rakuten Medical - To conquer cancer.","isPartOf":{"@id":"https:\/\/rakuten-med.com\/us\/#website"},"primaryImageOfPage":{"@id":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2025\/06\/26\/7908\/#primaryimage"},"image":{"@id":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2025\/06\/26\/7908\/#primaryimage"},"thumbnailUrl":"https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2025\/06\/P-1.-Press-release-photo.jpg","datePublished":"2025-06-27T00:00:36+00:00","breadcrumb":{"@id":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2025\/06\/26\/7908\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/rakuten-med.com\/us\/news\/press-releases\/2025\/06\/26\/7908\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2025\/06\/26\/7908\/#primaryimage","url":"https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2025\/06\/P-1.-Press-release-photo.jpg","contentUrl":"https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2025\/06\/P-1.-Press-release-photo.jpg","width":1566,"height":1044},{"@type":"BreadcrumbList","@id":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2025\/06\/26\/7908\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/rakuten-med.com\/us\/"},{"@type":"ListItem","position":2,"name":"Rakuten Medical and Orient EuroPharma Sign Exclusive Licensing Agreement for Alluminox\u2122 Platform-based Photoimmunotherapy in Taiwan, Malaysia, Singapore, and the Philippines"}]},{"@type":"WebSite","@id":"https:\/\/rakuten-med.com\/us\/#website","url":"https:\/\/rakuten-med.com\/us\/","name":"Rakuten Medical - To conquer cancer.","description":"Rakuten Medical, Inc. is a global biotechnology company developing precision, cell-targeting investigational therapies on its Alluminox\u2122TM technology platform. We are committed to our mission to conquer cancer and aim to achieve a society where cancer patients can lead fulfilling lives.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/rakuten-med.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/press_releases\/7908","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/press_releases"}],"about":[{"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/types\/press_releases"}],"author":[{"embeddable":true,"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/users\/2"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/media\/7912"}],"wp:attachment":[{"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/media?parent=7908"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}